Identifai Genetics Limited (ASX:ID1)

Market Cap	80.63M
Revenue (ttm)	n/a
Net Income	-2.58M
EPS	-2.11
Shares Out	191.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,232
Open	0.4200
Previous Close	0.4200
Day's Range	0.4200 - 0.4300
52-Week Range	0.2000 - 0.5600
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Jan 12, 2027

About Identifai Genetics

Identifai Genetics Limited provides prenatal genetic screening through the application of genome-wide sequencing and artificial intelligence in Israel, the United States, Hong Kong, China, and Australia. The company’s product, Windrose, is a first-trimester non-invasive prenatal test that provides cfDNA-based fetal risk assessment for more than 280 clinically actionable genes, all from a single blood draw and without requiring a partner sample. The company was founded in 2021 and is based in Subiaco, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ID1

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error